BORA PHARMACEUTICALS LTD (6472) - Cash Flow Conversion Efficiency
Based on the latest financial reports, BORA PHARMACEUTICALS LTD (6472) has a cash flow conversion efficiency ratio of 0.034x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$568.46 Million ≈ $17.91 Million USD) by net assets (NT$16.63 Billion ≈ $523.89 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of BORA PHARMACEUTICALS LTD for the company's overall valuation and market capitalisation.
BORA PHARMACEUTICALS LTD - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how BORA PHARMACEUTICALS LTD's cash flow conversion efficiency has evolved over time, based on yearly financial data.
BORA PHARMACEUTICALS LTD Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BORA PHARMACEUTICALS LTD ranked by their cash flow conversion efficiency. Explore 6472 cash to earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tibet Mineral Development Co Ltd
SHE:000762
|
0.009x |
|
Origin Bancorp, Inc.
NYSE:OBK
|
0.073x |
|
Holitech Technology Co Ltd
SHE:002217
|
-0.030x |
|
Eternal Asia Supply Chain Management Ltd
SHE:002183
|
-0.011x |
|
Chow Tai Seng Jewellery Co Ltd
SHE:002867
|
0.026x |
|
Concentrix Corporation
NASDAQ:CNXC
|
0.095x |
|
DCM Shriram Limited
NSE:DCMSHRIRAM
|
0.197x |
|
Beijing TRS Information Tech
SHE:300229
|
-0.003x |
Annual Cash Flow Conversion Efficiency for BORA PHARMACEUTICALS LTD (2019–2025)
The table below shows the annual cash flow conversion efficiency of BORA PHARMACEUTICALS LTD from 2019 to 2025. View BORA PHARMACEUTICALS LTD share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | NT$17.47 Billion ≈ $550.47 Million |
NT$4.24 Billion ≈ $133.64 Million |
0.243x | +271.59% |
| 2024-09-30 | NT$15.01 Billion ≈ $472.95 Million |
NT$980.81 Million ≈ $30.90 Million |
0.065x | -83.34% |
| 2023-09-30 | NT$11.77 Billion ≈ $370.69 Million |
NT$4.61 Billion ≈ $145.36 Million |
0.392x | +0.28% |
| 2022-09-30 | NT$5.14 Billion ≈ $161.95 Million |
NT$2.01 Billion ≈ $63.33 Million |
0.391x | -0.32% |
| 2021-09-30 | NT$3.15 Billion ≈ $99.32 Million |
NT$1.24 Billion ≈ $38.96 Million |
0.392x | +443.81% |
| 2020-09-30 | NT$2.46 Billion ≈ $77.65 Million |
NT$177.79 Million ≈ $5.60 Million |
0.072x | -48.53% |
| 2019-09-30 | NT$1.65 Billion ≈ $52.10 Million |
NT$231.77 Million ≈ $7.30 Million |
0.140x | -- |
About BORA PHARMACEUTICALS LTD
Bora Pharmaceuticals Co., LTD. engages in contract development, manufacture, and sale of pharmaceuticals in Europe, the United States, Taiwan, and internationally. The company operates through Sales, CDMO, and Other segments. It manufactures and sells generic, brand, and over the counter (OTC) drugs. The company also offers contract development and manufacturing services and technical services fo… Read more